




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A1	(11) International Publication Number: WO 99/44746
B01L 11/00, 3/02		(43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number:	PCT/IB99/00447	(74) Agent: MERCER, Christopher, Paul; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).
(22) International Filing Date:	4 March 1999 (04.03.99)	
(30) Priority Data:	60/076,769 4 March 1998 (04.03.98) US	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US):	ORTHO-McNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route No. 202, Raritan, NJ 08869-0606 (US).	
(72) Inventors; and		
(75) Inventors/Applicants (for US only):	LAURELL, Thomas [SE/SE]; Latinlinjen 9, S-224 73 Lund (SE). NILSSON, Johan [SE/SE]; Ostra Kennelvagen 7, S-237 35 Bjarred (SE). SANTESSON, Sabina [SE/SE]; Kristianstadsgatan 41B, S-214 35 Malmo (SE). NILSSON, Staffan [SE/SE]; University of Lund, Chemical Center, P.O. Box 124, S-221 00 Lund (SE). ZIVIN, Robert [US/US]; The R.W. Johnson Pharmaceutical Research Institute, 920 Route 202, P.O. Box 300, Raritan, NJ 08869 (US). THURMOND, Robin [US/US]; The R.W. Johnson Pharmaceutical Research Institute, 920 Route 202, P.O. Box 300, Raritan, NJ 08869 (US). PATEL, Lekha [US/US]; The R.W. Johnson Pharmaceutical Research Institute, 920 Route 202, P.O. Box 300, Raritan, NJ 08869 (US).	Published With international search report.

(54) Title: SYSTEM FOR PERFORMING ASSAYS ON A LEVITATED DROPLET



## (57) Abstract

The present invention relates to a system for performing small volume assays and the uses of the system. The system comprises a levitator for suspending a droplet, a dispenser for delivering a substance to the surface of the suspended droplet and a detector system for detecting changes in the droplet.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## SYSTEM FOR PERFORMING ASSAYS ON A LEVITATED DROPLET

The present invention relates to a system for performing small volume assays and uses of the system.

5

In order to reduce the volume of reagents used in performing assays, especially when expensive reagents are used, it is desirable to reduce the volume in which the assay is to be performed.

- 10 Other advantages obtained from reducing the volume of an assay include a reduction in waste generation and an increase in assay throughput, due in part to the ability to run reactions with higher target and ligand/substrate concentrations.

A problem with performing assays using small volumes is that, when the sample contacts  
15 the container wall, alterations of the sample composition by adsorption of the sample on the wall or by desorption of interfering substances from the wall may occur. Other problems with using small volumes include liquid handling, buffer evaporation and sensitivity of detection.

- 20 The use of "levitators" for the suspension of droplets has been known for a number of years. There are a number of different types of levitator which have been used to suspend droplets, including electrostatic and magnetic levitators, which depend on particular characteristics of the droplet such as charge, and acoustic levitators, which do not depend on particular characteristics of the droplet.

25

Levitators have been used to suspend droplets for the study of drop arrays (Yuren *et al.*, J. Aerosol Sci., 27, 721-737, 1996), to make micro and trace analyses using photometrical measurements of single suspended droplets (Welter *et al.*, J. Anal. Chem., 357, 345-350, 1997), to measure the time dependence of an acid-base reaction in a single levitated droplet (Trunk *et al.*, Chem. Phys. Lett., 264, 233-237, 1997) and to detect a single rhodamine 6G molecule in a levitated droplet (Barnes *et al.*, Anal. Chem., 65, 2360-2365, 30 1993).

A flow-through sampling cell for extracting a precise sample amount which may be used for the generation of small drops is disclosed in WO 97/01085. The use of the sample cell to form samples for electrophoresis is disclosed.

- 5 To the best of our knowledge, none of these prior art systems has been used to perform complete biochemical or cell-based assays, especially those directed toward the discovery of new drug candidates in a screening environment.

A problem with these prior art systems for suspending droplets is that evaporation of the  
10 droplet occurs. Evaporation from the droplet leads to changes in the concentration of the components in the droplet and therefore affects the assay conditions. In the prior art systems, in order to reduce evaporation, suspended droplets are coated with an oil or another material in order to reduce evaporation, or the droplet is suspended in an atmosphere saturated with water.

15 The present invention provides a system, which overcomes, at least in part, the problems of the prior art systems and allows the performance of assays in small volumes.

- The present invention provides a system for performing small volume assays comprising:  
20
- i. a levitator for suspending a droplet;
  - ii. a dispenser for delivering a substance to the surface of the suspended droplet; and
  - iii. a detector system for detecting changes in the droplet,
- 25 wherein the droplet is stably maintained by compensating for evaporation from the suspended droplet.

The system of the present invention can be used for the performance of an assay wherein a substance is added to the suspended droplet and the interaction of the added substance  
30 with the contents of the droplet is measured.

The system of the present invention has a number of advantages for the performance of assays.

- 1.The use of small volumes, approximately 1000-fold lower than possible with conventional instrumentation. This saves in materials and in the time needed for each assay. This also allows for studies to be carried out where the components are scarce such as hard to express proteins.
- 5
- 2.The avoidance of a container removes the problems associated with nonspecific binding to and contamination from container surfaces and reduces waste.
- 10 3.Improved sensitivity is obtained since the sample volume is low and the entire sample can be probed.
- 15 4.The dispenser for delivering a substance to the surface of the suspended droplet enables common reagents to be dispensed using the same dispenser since it never touches the complete assay mixture. For example, compounds can be injected using a low dead volume, continuous flow-through system (J. Nilsson *et al.*, Anal. Meth. Instr., Special Issue  $\mu$ TAS, 96, 88-91, 1996). This makes dispensing rapid and reduces waste. Another, commercially available dispenser suitable for this application is the remote mount "PixSys" device, from Cartesian Engineering, 17781 Skypark Circle, Irvine, CA 92714. Another device, recently described in the literature (Genetic Engineering News, 1998, 18(4), 16-17 from Packard Instruments (Meriden, CT), would 20 also be appropriate.
- 25 5.Stably maintaining the droplet by compensating for evaporation from the droplet enables assays to be performed in a physiologically stable environment, thereby avoiding erroneous assay results due to physiological changes to the suspended droplet, such as an increase in buffer concentration due to evaporation.
- 30 The levitator used in the system of the present invention can be any levitator, which suspends a droplet, including electrostatic, magnetic and acoustic levitators as mentioned above. Preferably, the levitator is an acoustic levitator. A suitable levitator is the

acoustical levitator APOS BA 10 with a standard frequency of 58kHz (Martinson Elektronic AB, Hagersten, Sweden).

The dispenser used in the system of the present invention can be any dispenser which is  
5 capable of delivering a substance to the surface of a suspended droplet. The dispenser may be a syringe such as a gas chromatography syringe. Preferably, the dispenser is a piezoelectric dispenser, such as the dispenser described by Hoffmann *et al.*, (Rev. Sci. Instrum., 63, 823-824, 1992), and most preferably, the dispenser is the flow-through sampling cell disclosed in WO 97/01085 and in Nilsson *et al.*, Anal. Meth. Instr., Special  
10 Issue  $\mu$ TAS, 96, 88-91, 1996. Such piezoelectric dispensers can eject droplets in the 50-100 picolitre range at a rate of one droplet to several hundred droplets per second. Other useful dispensers are described above.

The system of the present invention may comprise one or more dispensers wherein the one  
15 or more dispensers may be used to form a droplet and/or to add one or more substances to a droplet.

The substance to be added to the droplet may be any substance which enables an assay to be performed. The substance may be assayed itself or may assist in the performance of the  
20 assay. The substance may be a peptide, ligand, receptor, enzyme or drug compound, optionally labelled with, for example, a fluorophore. In a preferred embodiment, the substance added to the droplet is a substrate on which a component (e.g. an enzyme) present in the droplet acts to produce a detectable change.

25 The droplet is stably maintained by compensating for evaporation from the suspended droplet. The term "stably maintained" means that the suspended droplet has physiological stability, wherein physiological stability means that variations in the pH, ion concentration, buffer concentration, etc., within the suspended droplet are sufficiently small as to not significantly affect the assay result. Physiological stability is particularly  
30 important for enzymes and other substances which have a narrow physiological window of activity. An example of a particular enzyme which has a narrow physiological window of activity is the restriction endonuclease BamH1, which under conditions of low ionic strength, high enzyme concentration, high pH (>8.0) or high glycerol concentration

(>5%), can display new, less specific activities (New England BioLabs, 1996/7 catalog and references therein (see page 241)). Similarly, cell-based assays require the maintenance of tight regulation of environmental conditions to ensure both the fidelity of the induced physiologic events under study and the viability of the cells themselves  
5 (general requirements described in "Culture of Animal Cells" A Manual of Basic Techniques", 2<sup>nd</sup> ed., R. Ian Freshney, 1987, Alan R. Liss, Inc., NY, NY).

In a preferred embodiment, the suspended droplet is stably maintained by suspending the droplet in an atmosphere saturated with water. In a further preferred embodiment, the  
10 suspended droplet is stably maintained by delivering water to the suspended droplet thereby counteracting the effects of evaporation. In a further preferred embodiment, the suspended droplet is stably maintained by a combination of suspending the droplet in an atmosphere saturated with water and delivering water to the suspended droplet.

15 The rate of addition of water to the suspended droplet is dependent on a number of factors such as the evaporation rate from the droplet as well as the desired stable size of the droplet. Equilibrium will be reached between the rate of addition of water to the suspended droplet and the rate of evaporation from the droplet, at which point, the droplet will be maintained at a stable size.

20 The substance to be added to the droplet may also be any substance suitable for compensating for evaporation. Preferably, the substance is water.

25 Further information concerning the substances which may be delivered to the suspended droplet is given later when suitable assay formats are disclosed.

In a preferred embodiment, the one or more dispensers are used to deliver to the suspended droplet one or more substances to be assayed or substances which assist in the performance of the assay, and are also used to deliver water to the suspended droplet in  
30 order to compensate for evaporation from the droplet. Preferably, one dispenser is used to deliver to the suspended droplet one or more substances to be assayed or substances which assist in the performance of the assay and another dispenser is used to deliver water to the suspended droplet.

Preferably, the dispenser for delivering the substance to the surface of the suspended droplet is a piezoelectric dispenser and more preferably the dispenser for delivering the substance to the surface of the suspended droplet is the flow-through sampling cell 5 disclosed in WO 97/01085. The use of dispensers which deliver a substance to the surface of a droplet has the advantage that the risk of contamination is reduced as there is no contact between the dispenser and the suspended droplet.

The dispenser for delivering a substance to the suspended droplet can also be used to form 10 the suspended droplet. The dispenser may form one droplet that is to be suspended or may build up the droplet in stages by sequentially adding components thereby forming a suspended droplet. Alternatively, the suspended droplet can be formed by using a needle and a capillary smeared with sunflower or other suitable oil. The sample droplet is removed from the tip of the needle by the oily capillary and then deposited in the levitator. 15 An advantage of using the dispenser to form the droplet is that more control of the size of the droplet can be achieved, thereby enabling more consistent droplet sizes to be obtained.

In a preferred embodiment, the substance delivered to the suspended droplet using the system of the present invention is water.

20 In use, different dispensers can be used when adding different substances and the rate of use of the dispensers is preferably controlled so that evaporation is counteracted so that the size of the droplet remains the same. For example, when a substance such as an enzyme or substrate is added to the droplet, the size of the droplet changes and so the 25 concentrations of the reactants in the droplet change. Accordingly, the rate at which the different substances, i.e. the enzyme, substrate or water, are added, should be controlled so that evaporation is counteracted and the concentrations of the various reactants in the droplet are stably maintained.

30 The system of the present invention may comprises more than one levitator. When the system of the present invention does comprise more than one levitator, the dispensers for forming or delivering substances to suspended droplets may be used for more than one levitator. However, it is preferred that each levitator has a water dispenser associated with

it so that water may be continually delivered to the surface of the suspended droplet to counteract the effects of evaporation.

The detector system of the present invention may be any detector system suitable for  
5 detecting a change in the suspended droplet. The detector system may be used to detect fluorescence, radioactivity, chemiluminescence or colorimetric changes.

Suitable detector systems for use in the present invention are well known to those skilled in the art.

10

When fluorescence or colorimetric changes are being detected, the detector system preferably comprises a spectrophotometer arranged for irradiating the suspended droplet with light and detecting the emitted or reflected light. Suitable spectrophotometers include model MPF-2A from Perkin-Elmer, USA.

15

In an alternative embodiment of the present invention, when fluorescence or colorimetric changes are being detected, the detector system comprises a Mercury lamp for irradiating the suspended droplet and a charge coupled device (CCD) camera. A suitable detector system comprising a CCD camera and a mercury lamp is described in Nilsson, S., *et al.*, O 20 J. Capillary Electrophor. 1995, 2, 46; and Johansson, J., *et al.*, Anal. Chem., 1996, 68, 2766.

When chemiluminescence is being detected, the detector system preferably comprises CCD imaging as before or a Photo multiplier tube for single point detection.

25

When radioactivity is being detected, the detector system could be similar to that used for chemiluminescence (above), photon generation carried out by addition of a scintillant to the drop, preferably in the form of an SPA bead (Amersham, Plc.) to measure binding interactions.

30

The suspended droplet preferably has a volume of 1fl to 1ml, preferably 1fl to 100 $\mu$ l and more preferably 1pl to 1 $\mu$ l.

The suspended droplet may contain any substance. Preferred substances include proteins such as enzymes, enzyme substrates, antibodies or antibody fragments (Fab, F(ab')<sub>2</sub> and Fv fragments), peptides, proteases, receptors, ligands, hormones, and candidate drug molecules, as well as carbohydrates or other polymers and/or their ligands. Other preferred materials for inclusion in the drop are cells or cell fragments.

The suspended droplet may also contain whole cells. Suitable cells include any cell that can be suspended in culture medium. Particularly suitable cells include bacterial cells such as *E. coli* cells, mammalian cells such as Chinese Hamster Ovary (CHO) cells and NIH 3T3 cells, and yeast cells such as *S. cerevisiae* cells. If necessary, the suspended droplet can contain microsphere supports to which cells are attached. Suitable microsphere supports for attaching cells are well known to those skilled in the art and can be commercially obtained, for example CultiSpher.

The suspended droplet may contain beads impregnated or coated with substances for immobilising specific components such as receptors or ligands. Furthermore, the beads may be impregnated with fluorophores or other components which can detect bound compounds. Such impregnated beads are described in Udenfriend *et al.*, Anal. Biochem., 161, 494-500, 1987, herein incorporated by reference.

20

In a preferred embodiment, the system of the present invention comprises:

- 1           a central illumination source;
- 2           one or more dispensers for forming a suspended droplet and/or for delivering a substance to the surface of a suspended droplet;
- 25          3           one or more levitators positioned adjacent the illumination source and in a position wherein the suspended droplet can be illuminated by rotation of the illumination source; and
- 4           detectors positioned for measuring changes in the suspended droplets.

30

Preferably, the illumination source is associated with a mirror or other reflector, which can be used to cause the light emitted to be rotated around the central illumination source. Preferably, the mirror or other reflector is a one way rotating prism.

Preferably, the illumination source is a laser.

Preferably, a number of levitators are used so that a number of suspended droplets are  
5 formed around the central illumination source in a position so that each suspended droplet  
can be illuminated by the rotating light.

Preferably, the detectors are for detecting light absorbance or fluorescence from the  
suspended droplets. Accordingly, the detectors are positioned in different positions  
10 relative to the suspended droplets depending on whether they are detecting absorbance or  
fluorescence.

Preferably, the system also comprises an extractor to remove suspended droplets after they  
have been assayed, allowing rapid, serial use of each detector channel.

15

The present invention further provides the use of the system of the present invention in  
performing an assay.

20

Preferably, the system of the present invention is used in the performance of a screening  
assay for drug candidates.

In a preferred embodiment of the present invention, the system of the present invention is  
designed to perform rapid, sequential assays without the need for cuvettes, wells or  
capillaries.

25

As indicated above, the system is based on trapping and holding droplets, preferably in the  
pressure nodes of a standing ultrasonic field. Preferably, piezoelectric dispensers are used  
to dispense droplets into the field, using multiple injections to build the desired assay  
volume. Once there, dispensers are used to add additional components to the suspended  
30 droplet. Preferably, one dispenser adds water to compensate for evaporation. Reactions in  
the suspended droplet can be measured using optical techniques, such as by using a laser  
to cause fluorescence emission from the sample. As an example of a typical assay, an  
enzyme in an appropriate buffer is injected into the ultrasonic field, creating a droplet of

the desired volume. Next, a second dispenser adds to the droplet a substrate yielding a fluorescent signal when acted upon by the enzyme. The activity of the enzyme is then read by illuminating the entire droplet with a laser and detecting emission using either a PMT or CCD to detect fluorescence, absorbence, polarization, etc.

5

The system of the present invention is particularly useful in drug screening where an additional dispenser injects a compound of interest and its effects on the enzyme are observed. After analysis the drop is removed with an extractor or a stream of air and the next assay is performed.

10

Preferred assays to be performed using the system of the present invention are discussed below.

#### **Fluorescence Resonance Energy Transfer (FRET).**

15

This is a technique used for monitoring the activity of proteases (see Matayoshi *et al.*, Science, 247, 954, 1990 and Wang *et al.*, Tetrahedron Lett., 31, 6493, 1990). A peptide substrate is labelled with a matched pair of donor and acceptor fluorophores. Prior to cleavage, fluorescence is quenched due to FRET, as the fluorescent emission of the donor fluor is effectively absorbed by the acceptor dye. Upon cleavage of the labelled peptide, spatial separation of the fluorophores occurs, which results in a 40-50 fold increase in donor fluorescence. For this type of assay, the major advantage of using the system of the present invention is that the reaction volumes can be reduced by a factor of approximately 1000 compared to existing instruments. Similarly, FRET can be used to follow the interaction of two label materials (protein-protein, protein-ligand, etc.) as well as the effect of additional substances on the labelled pair (Patel, L.R., *et al.*, 1994, PNAS USA, 91, 7360-7364).

For example, the peptide KRPLGLARC can be cleaved by the matrix metalloproteinase, 30 matrilysin, between the alanine (A) and leucine (L) residues. The C-terminus cysteine can be labelled with AEDENS (a fluorophor excitable by light in the 300-400nm range, available from Molecular Probes, Eugene, OR) and the N-terminus can be labelled with DABCYL (a chromophor capable of absorbing the fluorescent output of AEDENS, when

brought in close proximity). This will result in a strong quenching of the AEDENS fluorescence. When matrilysin is present, the fluorescent intensity of AEDENS increases in a time dependent manner as the peptide is cleaved. This is based the distance between these two molecules, and therefore the presence or absence of enzyme activity (see  
5 Handbook of Fluorescent Probes and Research Chemicals, 6<sup>th</sup> edition, 1996, by Richard P. Haugland, Molecular Probes, Eugene, OR pp225-234).

The system of the present invention may therefore be used to detect the presence of matrilysin or any other proteinase.

10

#### **Fluorescence Polarization (FP).**

FP is a powerful technology for the study of molecular interactions in solution. See Jolley *et al.*, Biomol. Screening, 1, 33-38, 1996, and Dandliker *et al.*, Lab. Res. Methods Biol.  
15 Med., 4, 65-88, 1980. This technology has been extensively used in studies of small ligands binding to their receptors and can also be used to study the conversion of large molecules to small ones. It is unique among the methods used to analyse molecular binding because it gives a direct measure of the bound/free ratio without physical separation of bound tracer from free (unbound) tracer. FP measures the rotation of  
20 fluorescent molecules by changes in the polarization of the emitted light. If polarised light is used to excite a stationary fluorophore, it will also emit light at a particular polarization. However, if the fluorophore rotates between the time it absorbs and the time it fluoresces the polarization will change. Therefore, the rate of tumbling is related to the polarization of the emitted light. When a fluorescent ligand binds to a macromolecule, its rotation is  
25 greatly slowed and the polarization of the emitted light is more similar to that of the incident beam. When many molecules are present, the random tumbling will cause polarized light to be less polarized in the absence of the macromolecule, but will retain more of its polarization in its presence.  
  
30 In practice, a labelled ligand is measured in both the presence and absence of its receptor and an increase in FP indicates binding. In addition to soluble receptors, the binding of labelled ligands to membrane receptors can be carried out by injecting droplets containing cells or membranes and then levitating these droplets. A major advantage for the use of

FP assays in the system of the present invention is the lack of surfaces. Non-specific binding of the fluorophore to the surfaces of the container yields non-specific increases in FP.

- 5 For example, the binding of fluorescently labelled estrogen to the estrogen receptor can be measured using the technique. The increase in polarization as the ligand is bound to the receptor gives a direct read out of the binding.

#### **Homogeneous Time-Resolved Fluorescence.**

10

An instrument for carrying out this method is marketed commercially by Packard Instruments, among others. This method is a more specialised form of FRET described above (see Kolb *et al.*, J. Biomol. Screening, 1(4), 203-210, 1996, US-A-5,527,6847 and US-A-5,534,622). The technique uses Eu(3+) trisbipyridine cryptate (Eu(K)) as the donor 15 and modified allophycocyanin as the acceptor. The donor has a very long fluorescent lifetime whereas the acceptor's lifetime is relatively short. These time-resolved components result in a large increase in the signal to noise ratio. This is ideal for looking at the interaction between a labelled ligand and its labelled receptor since the average effective distances that can be examined for energy transfer are relatively large (>10nm), 20 allowing for rapid construction of assays.

For example, Src kinase is able to phosphorylate the peptide LCKVEKIGEGTYGVVYK on one or both of the tyrosines (Y). This peptide can also be biotinylated without affecting its utility as a substrate for Src. First, the reaction is carried out to phosphorylate 25 the peptide. Next, anti-phosphotyrosine antibody labelled with Eu(K) and allophycocyanin coupled to streptavidin are added. If the peptide is phosphorylated, the two components both bind to the peptide and the energy transfer can be measured. The use of this assay in the system of the present invention has the advantage of being able to make rapid, pipette-free additions of all of the components using very small volumes of 30 these expensive reagents.

#### **Chemiluminescence.**

CHEMILUMINESCENCE techniques like those marketed by Tropix are amenable for use in the system of the present invention. The technique relies on certain molecules that emit visible light upon their breakdown. This can be coupled to enzymatic modifications and therefore provides a readout of enzyme activity.

5

For example, Glucton® marketed by Tropix is a substrate for  $\beta$ -galactosidase. Upon cleavage by  $\beta$ -galactosidase, the product is unstable and, upon decay, emits light. This can readily be followed using a PMT.

#### 10 **Fluorescence Correlation Spectroscopy (FCS).**

FCS is described by Sterrer and Henko, J. Recept. Signal Trans. Res., 17, 511-520, 1997. FCS measures fluctuations in fluorescence as molecules move in and out of a small volume. Typically, small volumes are illuminated and as molecules diffuse into the 15 illuminated region they fluoresce. The diffusion into the illuminated region (i.e. sampling region) is a function of the number of molecules and the translational diffusion time. The measurements are taken in a time resolved manner and the number of molecules in the sample volume and the diffusion time can be computed using an autocorrelation function. The key is that smaller molecules diffuse faster than larger ones and can be readily 20 distinguished. An example would be detecting the ratio of free ligand to ligand bound to receptors. In the prior art instrumentation, this requires microtitre plates of high optical quality and the need for the plates to be agitated. The system of the present invention minimises both of these drawbacks since a cuvette is not used and the small volume allows for rapid diffusion throughout the entire drop in a short time.

25

For example, the estrogen receptor binding assay described under the FP section can also be probed using this method.

#### **Scintillation Proximity Assays (SPA).**

30

This technique is marketed by Amersham who have created beads which detect the proximity of tritium or  $^{125}\text{I}$  (Udenfriend *et al.*, Anal. Biochem., 161(2), 494-500, 1987 and Cook, Drug Discovery Today, 1(7), 287-294, 1996). In practice, the beads are coated with

membranes containing the receptor of interest. When a labelled ligand binds to the receptor it is in close enough proximity to excite fluorophores inside the beads and light is emitted. The system of the present invention is useful for such a method since there is no problem in levitating beads within droplets. The major advantage is that, since there are 5 no plates to hold the samples, the amount of radioactive waste becomes minimal.

For, example, SPA beads coated with wheat germ agglutinin can be used to immobilize human neuroblastoma cells expressing neuropeptide Y receptor. When this is mixed with <sup>125</sup>I labelled neuropeptide Y, binding can be detected by increases in emission from the 10 SPA beads.

### **Whole cell assays.**

The ability to dispense and levitate whole cells allows for many types of assays. Any cell 15 based assay that has a optical readout can be used in this system. Furthermore, anchorage dependent cells can be used in conjunction with microsphere supports.

For example:

1. Ligand induced fatty acid releases. This can be used as a general method for 20 detecting ligand/receptor interactions. NIH 3T3 cells are transfected with the receptor of interest and chimeric G-proteins, which couple it to the appropriate pathway. After differentiation into adipocytes, the cells release free fatty acids in response to the ligand. Because the volumes in this instrument are low, the pH of the entire droplet changes as a result of this and can be measured using standard pH sensitive dyes such as 8-25 hydroxypyrene-1,3,6-trisulphonic acid (HPTS).

2. Ligand induced Ca<sup>2+</sup> mobilization in cells. Cells expressing the receptor of interest and preloaded with fluorescent Ca<sup>2+</sup> chelator are levitated and the release of calcium monitored in response to the ligands.

30

3. Extracellular release of oxidative products. Neutrophils in the presence of OxyBURST Green H<sub>2</sub>HFF BS (Molecular Probes) are levitated and the release of oxidative products in response to ligands is measured by fluorescence. Once again the

advantage of small volumes greatly improves the sensitivity of this technique over conventional methods.

### Colorimetric Methods.

5

Most high sensitivity colorimetric assays currently used today could be used in this system, including colorimetric serine protease assays or  $\beta$ -galactosidase assays.

For example, the assay of proteases by diazotization of p-nitroaniline in microplates is a  
10 colrimetric assay. The protease assay consists of diazotization of p-nitroaniline, released from any p-nitroanilide substrate, with naphthylethylenediamine dihydrochloride to form a purple azo complex which can be measured at 540 nm. For example, trypsin, chymotrypsin, aminopeptidase, and elastase-like protease activities can be measured using benzoyl-Arg-p-nitroanilide, succinyl-Ala2-Pro-Phe-p-  
15 nitroanilide, Leu-p-nitroanilide, and succinyl-Ala3-p-nitroanilide at lower enzyme concentrations than previously detectable with these substrates. The basis of the assay is the Bratton-Marshall reaction, which allows improved sensitivity of the assay by increasing the maximum absorption of the product. This assay may have clinical applications in the measurement of leucine aminopeptidase in serum samples (see Lee *et*  
20 *al.*, *Anal. Biochem.*, 218(2), 480-482 (1994)).

Similarly, the presence or induction of the expression of glycolytic or other enzymes can be followed by the formation of highly colored or fluorescent products as a consequence of enzyme avtivity. Examples of these enzymes and substrates include  $\beta$ -galactosidease  
25 and 5-bromo-4-chloro-3-indolyl (chromogenic) or fluorescein diagalactoside (fluorogenic). Many other suitable enzyme/substrate pairs are described in Handbook of Fluorescent Probes and Research Chemicals, 6<sup>th</sup> edition, 1996, by Richard P. Haugland, Molecular Probes, Eugene, OR.

30 The present invention is now described in detail with reference to the following Figures and examples. It will be appreciated that the invention is described by way of example only and modifications of detail may be made without departing from the scope of the invention.

Figure 1 shows the instrumental set up for fluorescence measurements with a mercury lamp and CCD camera wherein (1) is an electromechanical shutter, (2) is an infrared filter, (3) is an NG-filter, (4) is a cylindrical lens, (5) is an interference filter (405 or 435nm), (6) 5 is an aperture, (7) is an interference filter (510nm), (8) is a lens system, (9) is a continuous microdispenser (CMD) and (10) is an injector.

Figure 2 shows two alternative set-ups for fluorescence measurements (Figure 2a and 2b, respectively).

10

Figure 3 shows a levitator and three dispensers wherein Dispenser I delivers single or several cells and may also deliver cells grown microcarriers. Dispenser II delivers water to keep the levitated droplet at a constant size and Dispenser III is used for delivering different types of analytes, for example drug- candidates.

15

Figure 4 shows fluorescence intensities (measured as peak height in mm) during droplet evaporation measured with fluorescence spectrophotometer (0.1 mM HPTS and 1.3% PCV in titration buffer).

20 Figure 5 shows fluorescence intensity ratio during droplet evaporation measured with fluorescence spectrophotometer (0.1 mM HPTS and 1.3% PCV in titration buffer).

Figure 6 shows fluorescence intensities (measured as peak height in mm) during lipolysis measured with fluorescence spectrophotometer (0.1 mM HPTS and 1.3% PCV in titration 25 buffer). Manual addition of about 1 µl of isoprenaline and insulin to the droplet after 2 and 7 minutes, respectively.

Figure 7 shows fluorescence intensity ratio during lipolysis in droplet measured with fluorescence spectrophotometer (0.1 mM HPTS and 1.3% PCV in titration buffer). 30 Manual addition of about 1 µl of isoprenaline and insulin to the droplet after 2 and 7 minutes, respectively.

Figure 8 shows fluorescence intensities during droplet evaporation measured with mercury lamp and CCD camera (1.0 mM HPTS and 1.3% PCV in titration buffer). Results evaluated with WinView 1.3.

- 5    Figure 9 shows fluorescence intensities during droplet evaporation measured with mercury lamp and CCD camera (1.0 nM HPTS and 1.3% PCV in titration buffer). Results evaluated with WinView 1.3.

10   Figure 10 shows fluorescence intensity ratios during droplet evaporation measured with mercury lamp and CCD camera (0.1 nM HPTS and 1.3% PCV in titration buffer). Results evaluated with WinView 1.3.

15   Figure 11 shows fluorescence intensities during continuous water addition with a CMD (operating at 10 Hz) to droplet measured with mercury lamp and CCD camera (10 nM HPTS and 1.3% PCV in titration buffer). Results evaluated with Drop.

Figure 12 shows fluorescence intensities during continuous water addition with a CMD operating with frequencies 10, 50 and 100 Hz, measured with mercury lamp and CCD camera (1 nM HPTS and 1.3% PCV in titration buffer). Results evaluated with Drop.

20   Figure 13 shows fluorescence intensities during lipolysis in droplet measured with mercury lamp and CCD camera (1 nM HPTS and 1.3% PCV in titration buffer). Manual addition of 1 µl of 300 nM isoprenaline and 1 µl of 1 nM insulin after 2 and 7.8 minutes, respectively. Results evaluated with Drop.

25   Figure 14 shows fluorescence intensity ratios during lipolysis in droplet measured with mercury lamp and CCD camera (1 nM HPTS and 1.3% PCV in titration buffer). Manual addition of 1 µl of 300 nM isoprenaline and 1 µl of 1 nM insulin after 2 and 7.8 minutes, respectively.

30   Figure 15 shows fluorescence intensities during lipolysis in droplet with continuous water addition with a CMD (operating frequency 10 Hz), measured with mercury lamp and

CCD camera (10 nM HPTS and 1.3% PCV in titration buffer). Manual addition of 1  $\mu$ l of 300 nM isoprenaline and 1  $\mu$ l of 1 nM insulin after 2 and 5.5 minutes, respectively.

Results evaluated with Drop.

- 5 Figure 16 shows fluorescence intensity ratios during lipolysis in droplet with continuous water addition with a CMD (operating frequency 10 Hz), measured with mercury lamp and CCD camera (10 nM HPTS and 1.3% PCV in titration buffer). Manual addition of 1  $\mu$ l of 300 nM isoprenaline and 1  $\mu$ l of 1 nM insulin after 2 and 5.5 minutes, respectively.
- Results evaluated with Drop.

10

Figure 17 shows the fluorescence intensity ratios of two experiments during 80 seconds with 0.5  $\mu$ l droplets containing 14 adipocytes each and 10nM HPTS in titration buffer. One of the experiments shows droplet evaporation and the other volume control using the CMD (at a frequency of 10 Hz) to add water to the droplet. The instrumental set-up included mercury lamp and CCD camera and the results were evaluated with Drop.

15

Figure 18 shows fluorescence intensity ratios during two experiments with lipolysis in 0.5  $\mu$ l droplets with continuous water addition using the CMD (operating frequency 10Hz), measured with mercury lamp and CCD camera. The droplets contained 12 adipocytes each and 10nM HPTS in titration buffer. The CMD was used to add 300nM isoprenaline to the droplet in both experiments after 35 seconds. The CMD was further employed to add 1nM insulin to the droplet in one of the experiments after 65 seconds. The instrumental set-up included mercury lamp and CCD camera, and the results were evaluated with Drop.

20

## EXPERIMENTAL

### EXAMPLE

30

In this example, adipocytes and the process of lipolysis have been the object of examination. The addition of adrenergic substances, in this case isoprenaline, to the droplet sets off the process of lipolysis in the cells. When free fatty acids are consequently

released from the cells, the pH of the surrounding buffer decreases. Addition of insulin stops the lipolysis and hence also stops the decrease in pH. By irradiating pH-dependent fluorophors in the buffer with light of specific wavelength, the changes in pH can be followed by continually monitoring the droplet with a charge coupled device (CCD) 5 camera.

The fluorophor used in the example is 8-hydroxypyrene-1,3,6-trisulphonic acid trisodium salt (HPTS), which is a highly water-soluble, membrane-impermeant pH indicator with a pKa of around 7.3 in aqueous buffers (depending upon ionic strength). This is in the 10 middle of the physiological pH range, which makes HPTS an ideal fluorophor for physiological pH-measurements (7-10). It exhibits a pH-dependent absorption shift and an emission maximum at 511 nm, allowing ratiometric measurements using an excitation ratio of 435/405 nm. The fluorescence of HPTS increases with pH when exciting at 435 nm and decreases with pH when exciting at 405 nm.. A disadvantage, however, is the 15 sensitivity of the method towards daylight, so titrations should preferably be performed in diffuse light or in the dark. During the experiments, the adipocytes were kept in a titration buffer with HPTS and a low buffering capacity.

Using a mercury lamp and a CCD camera, the fluorophor concentration detection limit 20 equalled an HPTS concentration in a droplet of 1 nM. Evaporation of the droplet was found to influence the fluorescence intensities, in that they increase when the droplet volume decreases. To avoid this, a continuous microdispenser (CMD) was used to continually add small amounts of water of the droplet to compensate for evaporation. When additives were introduced into the droplet, hence increasing droplet volume, this 25 also affected the intensities. The process of lipolysis was detectable both during evaporation and when the effects of evaporation were compensated for by the addition of water. Working with CMD, however, provided the best and most distinct results.

#### Adipocytes and buffers

30

Isolated adipocytes from male Sprague-Dawley rats, prepared by collagenase digestion, were kindly provided by Eva Degerman, MD, PhD, Section for Molecular Signalling,

Department of Cell and Molecular Biology, Center for Chemistry and Chemical Engineering, Lund.

The cells were kept suspended in a Krebs-Ringer-HEPES buffer pH 7.40 (NaCl, 118.6  
5 mM; KCl, 4.74 mM; CaCl<sub>2</sub>, 2.54 mM; KH<sub>2</sub>PO<sub>4</sub>, 1.19 mM; MgSO<sub>4</sub>, 1.19 mM; HEPES, 25 mM) containing 1.75% (w/v) bovine serum albumin (BSA), 2mM glucose and 200 nM adenosine (storage buffer). Every two hours, the storage buffer was removed and the cells were washed with new storage buffer.

10 Immediately before the levitated pH-stat titrations, the storage buffer was removed and replaced with a modified Krebs-Ringer buffer with low buffering capacity and pH 7.40 (NaCl, 131 mM; KCl, 4.74 mM; CaCl<sub>2</sub>, 2.54 mM; KH<sub>2</sub>PO<sub>4</sub>, 1.19 mM; MgSO<sub>4</sub>, 1.19 mM) containing 1.75% (w/v) BSA, 2 mM glucose and 200 nM adenosine (titration buffer). This medium also contained HPTS.

15 For experimental purposes, 100 µL of 13% (v/v) packed cell volume (PCV) was diluted to 1 mL in titration buffer containing HPTS, yielding a suspension of 1.3% PCV. (One mL PCV contains around 10<sup>7</sup> cells). As 2.5 µL droplets were used, this means that the cell number per droplet was approximately 325 cells. The actual number of cells was counted  
20 for some of the droplets. As the droplets were removed from the ultrasonic field by the capillary, they were placed on an objective glass and then counted in a microscope. In general, this showed that the estimation of 325 cells per droplet was accurate, although deviations did occur.

25 Additives for titrations

To start the lipolysis in the adipocytes, 1 µL of 300nM isoprenaline was used. The isoprenaline was obtained from Sigma, St Louis, Illinois, USA.

30 Human insulin was a kind gift from Novo Nordisk, Gentofte. One µL of 1 nM insulin was injected into the droplets to break off the process of lipolysis. The insulin was also meant to serve as a control to make sure that the cells had not been damaged during the previous

experiments, because if they had, the pH of the titration buffer would not stop decreasing when the insulin was added since all the fatty acids of the cells would have leaked out.

To check the changes in fluorescence emission of HPTS due to various pH values, 1  $\mu$ L sodium hydroxide of concentrations 1 mM and 0.5 mM, respectively, and 1  $\mu$ L acetic acid of concentrations 1 mM and 0.5 mM, respectively, was used.

#### The ultrasonic levitator

10 An ultrasonic levitator was used for the levitated titrations. The levitator is a device that generates a standing wave with equally spaced nodes and antinodes by multiple reflections between an ultrasonic radiator and a solid reflector. The levitator operates with a standard frequency of 58 kHz which means that the distance between the ultrasound transmitter and the reflector is approximately 1.7 cm, resulting in five nodal points of the standing wave.

15

#### Deployment of droplets and additives

To position the droplet in the ultrasound field, a 0.8x40 mm needle was used. The droplet of sample was removed from the tip of the needle by a capillary (TSP 025 375, Polymicro Technologies Inc., Phoenix, Arizona, USA) smeared with sunflower oil, after which it was deposited in the ultrasonic field.

20 The droplets were always positioned in the node directly above the middle of the levitator. This had practical and operational reasons only. As regards the droplet shape, the aim was always to keep the droplet as spherical as possible.

- 25 The average size of the droplets used was approximately 2.5  $\mu$ L. This was established by weighing a large number of droplets of water and calculating the volume.
- 30 Additives were manually introduced into the levitated droplet by a gas chromatography 5  $\mu$ L-syringe with a capillary fused silica needle (outer diameter 0.17 mm, 5A-SOC-100SA, Scientific Glass Engineering Inc., Austin, Texas, USA).

Water was continually added to the droplet by a continuous microdispenser (CMD), which was kindly provided by the Department of Electrical Measurements, Lund Institute of Technology, Lund. Connected to an injector, this was also used to introduce isoprenaline into the droplet. The dispenser used is that described by Nilsson *et al.*, (Anal. Meth. Instr., Special Issue  $\mu$  TAS, 96, 88-91, 1996).

#### Fluorescence measurements

To follow the release of protons from cells and the changes in pH, HPTS was used  
10 (obtained from Molecular Probes via LabKemi, Lund).

#### The fluorescence spectrophotometer

The fluorescence spectrophotometer used was a model MPF-2A from PERKIN-ELMER,  
15 USA, designed for the measurement of fluorescence excitation and emission spectra. It includes two grating monochromators, one for irradiating a sample with monochromatic light in the 200 to 700 nm range (excitation monochromator) and the other for permitting selective measurement of the intensity of the light emitted by the sample in the 220 to 800 nm range (emission monochromator). It also includes two lenses to focus the light in the  
20 sample cell and another lens to focus the emitted light into the emission monochromator.

The fluorescence spectrophotometer consists of a spectrophotometer (which contains the monochromators, two photomultipliers and a Xenon lamp source), a power supply for the lamp source, an amplifier and a recorder. The spectrophotometer sample compartment  
25 with cuvette holders and focusing lenses was removed and replaced with the levitator. The focusing lenses were taken apart, rearranged, and positioned to fit into the levitator. The lenses were positioned at exactly the right distance from the centre of the droplet in the levitator (the measured distance from the original lens position to the centre of the cuvette).

The measurements of droplet fluorescence were performed at excitation wavelengths of 405 and 450 nm and emission intensity was read at 511 nm. During the measurements, slit "16", filter "43", sample sensitivity "1" and scan speed "high" were used.

- 5 The fluorescence intensities were measured as peak height in mm.

Mercury lamp and CCD camera

The arrangement of the mercury lamp and the CCD camera is shown in Figure 1. The  
10 arrangement consists of a mercury lamp from OPSIS and a 600 µm optical quartz fibre. An electromechanical shutter connected to a shutter control, a pulse generator PM5705 from Philips, and a LF synthesiser PM5190, also from Philips. The synthesiser was also connected to the CCD controller.

15 The shutter was followed by an infrared filter (BG38), NG-filters, a cylindrical lens (diameter 5cm, focal distance 5 cm), interference filters and an aperture. To avoid the negative effects of droplet evaporation, a continuous microdispenser (CMD) was used. The CMD was connected to a pulse/function generator 8111A and a power supply unit E3612A from the Hewlett Packard. The CMD was later connected to an injector, so it  
20 would be possible to introduce small enough amounts of the isoprenaline as not to change the droplet volume, and hence the fluorescence intensities, drastically.

At the other side of the levitator, at a 90° angle, an interference filter (510 nm) and a lens system (focal distance 75 mm) were placed, followed by a CCD camera from Princeton  
25 Instruments Inc., that has 1100x330 pixels and was cooled with Peltzier elements. The arrangement was connected to a computer that collected the information.

To evaluate the results, the computer program WinView 1.3 was first used. The maximum intensity values of the droplet fluorescence intensity were used as an  
30 approximation of the total intensities.

The total intensity values were subsequently calculated.

## RESULTS AND DISCUSSION

### Manual deployment of droplets and additives

- 5 For manual deployment of droplets in the ultrasonic field a syringe and needle of appropriate size is used. For adipocytes in solution, a 0.8x40 mm needle was chosen so as to avoid mechanical lysis of the cells.

To facilitate the detachment of a droplet from the needle, a capillary smeared with  
10 sunflower oil was used. This pale yellow oil was chosen so as not to interfere with the measurements by means of background fluorescence. The sample droplet is removed from the tip of the needle by the oily capillary and is then deposited in the ultrasonic field. To further facilitate the positioning of the droplet, the reflector distance of the levitator can be slightly changed. The deployment of droplets in the ultrasonic field also  
15 becomes easier with the use of maximum ultrasonic power.

After deployment in the ultrasonic field the droplet may perform oscillations. The droplet can be stabilised by adjusting the reflector distance or by decreasing the ultrasonic power. When maximum power is used, the droplet will always be flat and  
20 deformed, so in order for the droplet to be spherical, the ultrasonic power needs to be low. High ultrasonic power may also induce a kind of boiling phenomenon in the droplet, which is to say that bubbles of air make the liquid look as if it was boiling. Once formed, these bubbles are hard to get rid of, so if this occurs, it is better to remove the droplet and lower the ultrasonic power before trying again, either with the same  
25 droplet or with a new one. The bubbles disappear quickly once the droplet is outside the ultrasonic field, and since they do not seem to affect the droplet or its contents in any measurable way, it is often easier to use the same droplet when trying again.

Additives can be manually introduced into the levitated droplet by a gas  
30 chromatography syringe (although preferably, a piezoelectric dispenser or the like introduces the additives). The capillary needle does not disturb or attract the droplet from its node. This method works equally well for the addition of both liquids and

solids. If solids are to be introduced, the capillary needle should be lightly dipped in the substance of interest before being introduced into the droplet.

### The fluorescence spectrophotometer

5

#### Background fluorescence measurements

Experiments with no droplet in the levitator gave no peaks for either of the excitation wavelengths. A droplet of water (without any fluorophor present) gave no peaks either, 10 and there was no difference if the droplet of water was placed in the middle node or in the nodes above or below the middle, or if the ultrasonic power used was high or low.

#### Determination of fluorophor concentration detection limit

15 Different concentrations of HPTS were tested and 0.1 mM (in titration medium) was found to be the best for these measurements. Although the concentration of 10 µM was also detectable, it yielded very low peaks that proved difficult to evaluate properly.

Concentrations higher than 0.1 mM gave peaks of great height as well as width, but 20 since the concentration of 0.1 mM HPTS had proved satisfactory; this line of experiment was not pursued further. If the fluorophor concentration is kept as low as possible, it is less likely that the cell and the reactions will be affected in undesirable ways by the fluorophor.

25 Acid/base experiments and droplet

To test the HPTS dependence on changes in pH, acetic acid and sodium hydroxide were introduced in to the droplet (1 mM HPTS in water) in various quantities and ratios. The results are listed in Table 1. The fluorescence intensity, measured as peak height, 30 decreases with decreasing pH when the excitation wavelength of 435 nm is being used. When this wavelength is 405 nm, the fluorescence intensity increases with decreasing pH.

The intensity ratio (435/405) decreases with decreasing pH and increases with increasing pH.

*Table 1. Intensities (measured as peak height in mm) and intensity ratios after addition of acetic acid ( $\text{CH}_3\text{COOH}$ ) and sodium hydroxide ( $\text{NaOH}$ ) to 2.5  $\mu\text{L}$  droplet (HPTS concentration in water, 1 mM).*

Additives	Intensity <sub>435nm</sub> (mm)	Intensity <sub>405</sub> (mm)	Intensity ratio <sub>(435/405)</sub>
None	51	84	0.61
1 $\mu\text{L}$ 1 mM $\text{CH}_3\text{COOH}$	34.5	98	0.35
2 $\mu\text{L}$ 1 mM $\text{CH}_3\text{COOH}$	29	111	0.26
2 $\mu\text{L}$ 1 mM $\text{CH}_3\text{COOH}$ and 1 $\mu\text{L}$ 1 mM $\text{NaOH}$	67	106	0.63
2 $\mu\text{L}$ 1mM $\text{CH}_3\text{COOH}$ and 2 $\mu\text{L}$ 1mM $\text{NaOH}$	86	104	0.84

#### Droplet evaporation

10

The fluorescence intensities were found to be affected by continuous evaporation from the droplet. Figure 4 shows that both wavelength intensities (measured as peak height in mm) decreases with time and evaporation. This decrease is greater and more marked for the excitation wavelength 405 nm, but the decrease also affects excitation at the wavelength 435nm.

15

This decrease is due to the fact that the HPTS concentration of 0.1 mM is too high to be useful. When droplet evaporation occurs, the fluorophor concentration increases to a point where it leads to self-absorption. Even though the fluorophor concentration increases, the instruments will detect less intensity.

20

The evaporation also results in an increase of the intensity ratios with time and evaporation (Figure 5). This will present a real problem when small changes in pH are to be measured, since it will be very difficult to establish whether a rise or fall in intensity is due to volume change or pH change.

25

Lipolysis in droplet

Experiments were performed to establish whether the process of lipolysis in the cells in the droplet was detectable. Figure 6 shows fluorescence intensities (measured as peak height in mm) during such an experiment. One  $\mu\text{L}$  of isoprenaline and insulin were added to the droplet after 2 minutes and 7 minutes, respectively.

The intensity of the excitation wavelength 405 nm decreases evenly for about 6 minutes, at which time the intensity leaps upward until the addition of insulin seemingly makes it decrease again. However, the intensity should increase with decreasing pH (that is, after the addition of isoprenaline). When insulin is added, the intensity should stop increasing since the process of lipolysis is stopped. For the excitation wavelength 435nm, the opposite should occur.

This is clearly not the case for any of the wavelength intensities. It seems likely that this, at least partly, is an effect of droplet evaporation; as Figure 4 shows, the 405 nm intensity decreases with time and decreasing volume. It is difficult, however, to explain the sudden leap upward in intensity at the time of 6 minutes. This is obviously not connected in any way to the addition of isoprenaline or insulin and the consequent volume changes. More probable is the explanation that the high fluorophor concentration makes it impossible to get any reliable results.

The fluorescence intensity ratios from the same experiment are demonstrated in Figure 7. When only evaporation is involved, the ratio increases evenly with time (Figure 5), but this is not the case here. There is a definite levelling of the ratio values during the time when lipolysis should be occurring within the droplet. That is what would have been expected, according to theory, although considering the behaviour of the intensity values and the fact that the high fluorophor concentration gives rise to self-absorption, this is not enough to conclude that the process of lipolysis is detectable with this method.

**Mercury lamp/CCD camera measurements**

Background fluorescence measurements

To acquire the background intensity, experiments with no droplet in the levitator were performed at the excitation wavelength of 405 nm. It was not practically possible to 5 acquire background images at both excitation wavelengths during one series of measurements. However, the background acquired when exciting at 435nm did not differ significantly from the one acquired at 405 nm.

Position, shape and size of droplet

10

As a rule, the droplets were always positioned in the node directly above the middle node of the levitator (the second node). This was for practical and operational reasons only.

15 The droplet was kept as spherical as possibly by adjusting the ultrasonic power of the levitator.

The average size of the droplets used was approximately 2.5  $\mu\text{L}$ , although the droplets placed manually in the levitator were of slightly different sizes. This causes several 20 problems, as will be shown below, so it is preferred to position the droplet using a piezoelectric dispenser or the like, so that the droplets will be of exactly the same volume every time.

Experiments were performed trying to minimise droplet size by letting the droplet partly 25 evaporate and then employing the CMD to keep this smaller volume constant. This approach was only partly successful. The minimising of droplet volume worked well, yet other problems arose. It was simply impossible to manually introduce additives into these small droplets, since they attached themselves to the capillary of the GC-syringe much more readily than larger droplets. Once attached to the capillary, there was no 30 way to reposition them in the ultrasonic field. However, this approach works well when the additives are introduced with a piezoelectric dispenser, a CMD or a similar device.

Determination of fluorophor concentration detection limit

The experiments show that nanomolar concentrations of the fluorophor are detectable with this method. As yet, fluorophor concentrations of 100 nM, 10 nM and 1 nM have 5 proven appropriate. By using different filters and adjusting the focus of the excitation light, the intensities resulting from the different concentrations can be optimised. For reasons mentioned above, the lowest fluorophor concentration of 1 nM was chosen for further experiments. It is possible, however, that even lower concentrations of the fluorophor may be detectable.

10

Experiments were also performed using a fluorophor concentration of 0.1 mM (Figure 8) to compare with the results from the evaporation measurements with the fluorescence spectrophotometer (Figure 4). The results show that this concentration might well be used in this experimental set-up; however, it is too high to be of any real interest except 15 when compared to the spectrophotometer results.

Acid/base experiments with droplet

To test the HPTS dependence on changes in pH, acetic acid and sodium hydroxide of 20 different concentrations were introduced into the droplet (10 µM HPTS in water). The results, listed in Table 2, shows that the intensity ratios (435/405) vary with pH according to theory, while the fluorescence intensities for each wavelength are more complicated to evaluate.

25 The fluorescence intensity at 435 nm increases with decreasing pH of the droplet as expected, but for the excitation wavelength 405 nm, the picture is more complicated. The intensity is higher when 1 µL 100 nM sodium hydroxide is added than when 1 µL 100mM acetic acid is added, and this is not in accordance with theory. It is likely that this effect is due to different droplet volumes. The excitation wavelength of 405 nm has 30 proven to be more sensitive than 435nm and could well be affected in this way even by very small changes in volume and droplet size. The important information is anyhow to be found in the intensity ratio, and these behave fully as expected.

*Table 2. Intensities and intensity ratio after addition of acetic acid ( $\text{CH}_3\text{COOH}$ ) and sodium hydroxide ( $\text{NaOH}$ ) to 2.5  $\mu\text{L}$  droplet (HPTS concentration in water 10  $\mu\text{M}$ ). Results evaluated with WinView 1.3.*

Additives	Intensity <sub>435 nm</sub>	Intensity <sub>405 nm</sub>	Intensity ratio <sub>(435/405)</sub>
1 $\mu\text{L}$ 100 mM NaOH	1611	1442	1.12
1 $\mu\text{L}$ 100 mM $\text{CH}_3\text{COOH}$	0	1289	0
1 $\mu\text{L}$ 10 mM $\text{CH}_3\text{COOH}$	651	2027	0.32

5

#### Droplet evaporation and the continuous microdispenser

The fluorescence intensities were affected by the continuous evaporation of the droplet in this instrumental set up. Figure 9 shows that both wavelength intensities increase 10 with time and evaporation; the opposite phenomenon to that encountered with the fluorescence spectrophotometer (Figure 4). The intensities increase for both excitation wavelengths, although the increase is greatest for the excitation wavelength 405 nm.

This increase is due to the increasing concentration of the fluorophor that results from 15 the evaporation of water, and this also affects the intensity ratios (Figure 10). The intensity ratio increases with time and evaporation, just as it did when the fluorescence spectrophotometer was used, and it gives rise to the same problem in this application. When lipolysis is occurring in the adipocytes in the droplet, that is, when the pH of the buffer is decreasing, the intensity ratio should also decrease. But since it is in fact 20 increasing over time, this will shield the expected change in intensity from both excitation wavelengths and from the intensity ratio as well.

The increase in fluorescence intensities due to droplet evaporation can be avoided if water is continuously added to the droplet in small amounts. Figure 11 shows 25 fluorescence intensities during 10 minutes when a continuous micro dispenser (CMD) was used to keep the droplet volume as close to constant as possible. The CMD was operating with a frequency of 10 Hz, which equals an addition of water of approximately 1 nL/s. The results were evaluated with the computer program Drop, and enabled the use of the total intensity values. The results were compared with those 30 displayed in Figure 6 (evaluated with WinView 1.3).

Figure 11 shows the increase in fluorescence intensity with decreasing droplet volume has apparently ceased for both excitation wavelengths. This means that the detection of changes in fluorescence intensity due to small changes in pH can be detected with this  
5 method.

Figure 12 shows fluorescence intensities for the excitation wavelengths of 405 nm during continuous water addition to a 2.5  $\mu$ L droplet of 1 nM HPTS and 1.3% PCV. The CMD was operating with the different frequencies of 10, 50 and 100 Hz. When the  
10 lower frequency is used, the intensity values form a straight line, but as the frequency increases, the intensity values decrease, responding to the volume change of the droplet when more and more water is added. This shows the importance of choosing the right CMD frequency and what will happen if too much or too little water is added to the droplet.  
15

The original size of the droplet also affects the choice of appropriate CMD frequency. Small droplets will evaporate at a higher rate than larger droplets and therefore will need adding of water at higher frequencies than larger droplets. On the other hand, too high a CMD frequency will slowly increase the droplet volume.  
20

This problem is easy to solve by simply choosing a frequency to be used and then letting the droplet volume stabilise itself. If the chosen frequency is too high for the droplet in question, the droplet volume will increase up to a point where the CMD at the current frequency will keep it constant. If the chosen frequency is too low, then the  
25 droplet will evaporate until it reaches the point where the volume corresponds to the CMD frequency. This done, the fluorescence intensity values will be stabilised.

Figure 17 shows a comparison between droplet evaporation and droplet volume control using the CMD during 80 seconds. During the volume control experiment, the CMD  
30 was operated with a frequency of 10Hz, approximately adding 1nL/s of water. It is clear from the result in Figure 17 that the CMD stabilises droplet volume and fluorescence.

Another problem, however, remains. Even if the volume change caused by evaporation can be avoided, the adding of the isoprenaline and the insulin also affects droplet volume. Not only will the intensity values decrease in response to drastically changed droplet volume, but the CMD frequency will no longer be optimised, so evaporation 5 will occur again. The solution is to introduce the additives in very small amounts with a CMD or in solid form, neither of which would cause any drastic volume changes.

An injector was connected to the CMD to allow injection of isoprenaline in small amounts. This did not work out too well, largely because it takes time to rinse the CMD 10 with the isoprenaline solution, time when droplet evaporation can and does occur. This means that before the CMD can be applied to add isoprenaline to the droplet, the evaporation already has proceeded to a point where the CMD frequency ought to be changed, only now there is no way to determine what frequency would be appropriate. The solution of isoprenaline does provide additional water to the droplet, but it also 15 provides isoprenaline that will set off the lipolysis of the cells in the droplet, and so it is impossible to stabilise the intensity values before performing the measurements. It is preferred to use one CMD for just water and one for each additive, wherein the CMDs not in use are turned off, while the one needed for the moment provides both water and the additive in question. This way, it does not take any time between turning off the 20 CMD that adds just water and turning on the CMD that provides the additive.

If the reagents are to be introduced as solids, other problems arise. It is quite easy to introduce solids into the droplet by using a capillary dipped in the substance of interest and then placed into the levitated droplet. It is also a quick method, hardly consuming 25 enough time to cause problems with evaporation and CMD frequency. But with this method it is impossible to determine the amount of reagent on the capillary and the concentration of the reagents once they enter the droplet. The dissolving of the reagent in the droplet will be different every time, since the mixing procedure is affected by droplet features like shape, spinning and streams within the droplet.

30

Lipolysis in droplet

Figure 13 and Figure 14 show fluorescence intensities and intensity ratios (435/405) during an experiment where the process of lipolysis in the cells in the 2.5  $\mu$ L droplet was started by the addition of approximately 1  $\mu$ L of 300 nM isoprenaline to the droplet, and then stopped by the addition of around 1  $\mu$ L of 1 nM insulin. The 5 fluorophor concentration used was 1 nM HPTS in titration buffer with 1.3% PCV.

During this experiment, the CMD was not used; that is to say, no additional water was added to the droplet except what was present in the solutions of isoprenaline and insulin.

After the addition of isoprenaline, the intensities for both excitation wavelengths 10 decrease immediately. This is caused by the increase in droplet volume and the subsequent decrease of the fluorophor concentration. The same phenomenon occurs after the addition of insulin, and is caused by the same thing. The effects also show that when the intensity ratio is measured, the ratio decreases when the volume increases.

15 For the excitation wavelength 405 nm, the intensities then continue to rise after the addition of isoprenaline. This would be the case anyhow, even if there were no reaction going on in the droplet, because of the evaporation, but it is likely that the increase in intensity in that case would be slower. If this were solely an effect of evaporation, the intensities would not form such a steep line. When the droplet volume increases, the 20 evaporation rate normally decreases.

Comparison of Figure 13 with Figure 11 shows that in both cases, the intensity values for the excitation wavelength 405 nm range over approximately 100000 units, a spread 25 that might suggest that the apparent rise of the intensity values in Figure 13 is in fact no true rise. The fluorophor concentration, however, was not the same in these two experiments. Figure 13 displays results from an experiment when a fluorophor concentration of 1 nM was used, whereas Figure 11 shows results obtained with a fluorophor concentration of 10 nM. The lower fluorophor concentration gives rise to lower intensity values than the higher concentration, making a comparison of the results 30 in Figures 13 and 11 difficult.

For the excitation wavelength 435 nm, the picture is quite different. After the addition of isoprenaline, the intensities form a straight line. If lipolysis had occurred, it would be

expected that the intensities would be decreasing. But on the other hand, if evaporation were the only phenomenon here, the intensities would increase slowly with time. Since this is not the case, it must be concluded that the seemingly straight line is in fact a decrease in intensity that is shielded by the evaporation effects.

5

The intensity ratios (Figure 14) do decrease after the addition of isoprenaline and then continue to do so until the addition of insulin. This decrease is not great, but considering the small changes in pH in the droplet, this is nothing more than could be expected.

10

Figure 15 and Figure 16 show a similar experiment, but now with continuous addition of small amounts of water with the CMD to avoid the effects of evaporation. The CMD was operating at a frequency 10 Hz (approximately adding water at a rate of 1 nL/s). The process of lipolysis in the adipocytes in the 2.5  $\mu$ L droplet was started by the 15 addition of approximately 1  $\mu$ L of 300 nM isoprenaline to the droplet, and then stopped by the addition of around 1  $\mu$ L of 1 nM insulin. The fluorophor concentration used was 10nM HPTS in titration buffer with 1.3% PCV.

20

Before the addition of isoprenaline, the intensities for both excitation wavelengths should form a straight line. This is not quite the case for any of them, intensities slightly increasing despite the presence of the CMD. This suggests that the effects of evaporation were not totally absent when this experiment was performed, and that the stabilising of the intensity values and the volume of the droplet should have been allowed to go on for some time longer. The addition of isoprenaline and insulin also 25 affects droplet volume, so that the intensities in both cases decrease immediately after an addition, as could be expected.

30

After the addition of isoprenaline and the initial decrease in intensity, the intensities for the excitation wavelength 405 nm start to increase. For the excitation wavelength 435 nm, the intensity also decreases initially in response to the added volume and then continues to decrease for as long as the isoprenaline stimulation lasts. This decrease is not marked but is clearly visible. For both excitation wavelengths, these are effects

indicating the decrease in pH was set off by the addition of isoprenaline and the subsequent start of lipolysis.

It is important to remember that the CMD in the present experiments cannot be expected  
5 to flawlessly prevent the effects of evaporation once an addition of reagent is made,  
since this changes the volume drastically. It may be that larger droplets evaporate more  
slowly than smaller ones, but nevertheless there will be evaporation occurring. After  
the addition of isoprenaline, the CMD frequency of 10 Hz is no longer enough to keep  
the volume constant (especially since this does not seem to have been quite the case  
10 even before the addition of isoprenaline, although to a lesser degree). This means that  
even though the CMD was used, evaporation has occurred, shielding part of the pH-  
dependent intensity changes.

The same effects could be expected after the addition of insulin, and probably to a larger  
15 degree since it is the second time in a short while that the droplet volume increases  
drastically. For the excitation wavelength 405 nm, this seems not to be the case, but for  
the wavelength 435 nm there is no doubt that the intensities start increasing after the  
adding of insulin.

20 The intensity ratios (Figure 16) decrease according to theory when isoprenaline is added  
and start to increase when insulin is added. The latter is probably an effect of  
evaporation.

Figure 18 shows the change in intensity ratios of two experiments where a CMD was  
25 used to keep the droplet volume constant and two other CMDs were used for reagent  
addition. The lipolysis of 12 adipocytes was studied in 0.5 $\mu$ l droplets. The fluorophor  
concentration used was 10nM HTPS in titration buffer. Initially, the intensity ratios  
formed straight lines that decreased when 300nM isoprenaline was added. In one of the  
30 experiments, 1nM insulin was later added and the intensity ratios then stabilised to form  
a straight line again. In the other experiment, no further additions were made and the  
decrease in intensity ratios continued throughout the experiment. This clearly shows  
that the use of the CMD eliminates the problem with volume changes in the levitated  
droplet.

## CONCLUSIONS

It has been shown that the process of lipolysis in adipocytes in a levitated buffer droplet  
5 is detectable with this method. Advantages of the method are the small amounts of  
essentially everything needed for the experiments, such as fluorophor, cells, reagents  
and so on. It is also a quick method, once the procedures have been optimised. The  
absence of contacting surfaces is also a major advantage, since the droplet is in fact a  
small container without walls.

10

The use of the CMD in the study to avoid the evaporation of the droplets has proven  
advantageous. It has been shown that with this device, the fluorescence intensity values  
stabilise, an important feature when performing these experiments. One CMD is needed  
at all times to keep the evaporation under control. Preferably another CMD is used for  
15 adding reagents to the droplet, since this would mean that far smaller volumes of  
reagents could be added, small enough not to give unwanted volume effects.

## CLAIMS

1. A system for performing small volume assays comprising:
  - 5 i. a levitator for suspending a droplet;
  - ii. a dispenser for delivering a substance to the surface of the suspended droplet; and
  - iii. a detector system for detecting changes in the droplet,
- 10 wherein the droplet is stably maintained by compensating for evaporation from the droplet.
2. A system according to claim 1 wherein the levitator is an acoustic levitator.
- 15 3. A system according to any one of claim 1 or claim 2 wherein the dispenser is an piezoelectric dispenser.
4. A system according to any one of claims 1 to 3 wherein the substance delivered to the surface of the suspended droplet is any substance which enables an assay to be 20 performed.
5. A system according to claim 4 wherein the substance delivered to the surface of the suspended droplet is a peptide, ligand, receptor, enzyme or drug compound, optionally labelled.
- 25 6. A system according to any one of claims 1 to 3 wherein the substance to be delivered to the surface of the suspended droplet is any substance suitable for counteracting the effects of evaporation.
- 30 7. A system according to claim 6 wherein the substance to be delivered to the surface of the suspended droplet is water.

8. A system according to any one of the previous claims wherein there is more than one dispenser and more than one substance is delivered to the surface of the suspended droplet.

5 9. A system according to any one of the previous claims wherein the detection system detects changes in absorbance, fluorescence, radioactivity, chemiluminescence or colorimetry.

10. A system according to any one of the previous claims wherein the droplet is in the  
10 range of 1fl to 100 $\mu$ l.

11. A system according to any one of the previous claims wherein the droplet contains a protein, an enzyme, an enzyme substrates, antibodies or antibody fragments, peptides, proteases, receptors, ligands, hormones or a drug molecule.

15 12. A system according to any one of claims 1 to 10 wherein the droplet contains cells.

13. A system according to any one of claims 1 to 10 wherein the droplet contains beads.

20 14. A system according to claim 1 comprising:  
1 a central illumination source;  
2 one or more dispensers for forming a suspended droplet and/or for delivering a substance to the surface of a suspended droplet;  
25 3 one or more levitators positioned adjacent the illumination source and in a position wherein the suspended droplet can be illuminated by rotation of the illumination source; and  
4 detectors positioned for measuring changes in the suspended droplets.

30 15. A system according to claim 14 wherein the illumination source is associated with a mirror or other reflector, which causes the light emitted to be rotated around the central illumination source.

16. A system according to claim 14 or claim 15 wherein the illumination source is a laser.


5 17. A system according to any one of claims 15 to 16 wherein there are a number of levitators arranged so that the suspended droplets are positioned around the central illumination source so that each suspended droplet can be illuminated by the rotating light.


18. The use of the system of any one of claims 1 to 13 in an assay.

10


19. The use of the system of any one of claims 1 to 13 in an assay screening for drug candidates.

1/12









3/12




4/12

**FIG. 3****FIG. 4**


5/12

**FIG. 5****FIG. 6**



6/12



**FIG. 7**

7/12



**FIG. 8**

8/12



**FIG. 9****FIG. 10**

**FIG. 11****FIG. 12**



10/12

**FIG. 13****FIG. 14**

11/12

**FIG. 15****FIG. 16**

12/12

**FIG. 17****FIG. 18**

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/IB 99/00447

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 B01L11/00 B01L3/02

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 B01L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 38 06 634 A (BATTELLE INSTITUT E V) 14 September 1989 see the whole document ---	1,2,6,9, 14
A	US 5 275 787 A (YUGUCHI NAOKI ET AL) 4 January 1994  see abstract; figures 1-4,12 see column 3, line 37 - column 4, line 34 see column 5, line 13 - column 5, line 29 see column 7, line 47 - column 8, line 49 ---	1,3,8,9, 12-14, 16,18,19
A	US 5 558 837 A (TSUKISHIMA CHIHIRO) 24 September 1996 see abstract; figures 1,15-21 see column 8, line 55 - column 9, line 60 see column 15, line 18 - column 18, line 29 --- -/-	1-4,18

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

4 June 1999

17/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Runser, C

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/00447

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 27 09 698 A (BATTELLE INSTITUT E V) 7 September 1978 see page 5 – page 10 see page 20 – page 21 see figures 1,7 ---	1,2,9, 14,18
A	WO 97 01085 A (DROTT JOHAN ;NILSSON JOHAN (SE); LAURELL THOMAS (SE); NILSSON STAF) 9 January 1997 cited in the application see the whole document ---	1,3,14
A	LIU H ET AL: "ANALYTICAL CHEMISTRY IN A DROP" TRAC, TRENDS IN ANALYTICAL CHEMISTRY, vol. 15, no. 9, 1 October 1996, pages 468-475, XP000641955 see the whole document ---	1,4,9, 14,18,19
A	TRUNK ET AL.: "Microchemistry : time dependence of an acid-base reaction in a single optically levitated microdroplet" CHEMICAL PHYSICS LETTERS, no. 264, 3 January 1997, pages 233-237, XP002104886 cited in the application see the whole document -----	1,9

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/00447

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
DE 3806634	A	14-09-1989	NONE		
US 5275787	A	04-01-1994	JP	4048245 A	18-02-1992
			JP	2749906 B	13-05-1998
			JP	3122548 A	24-05-1991
			DE	69025370 D	28-03-1996
			DE	69025370 T	12-09-1996
			EP	0421406 A	10-04-1991
US 5558837	A	24-09-1996	JP	7275690 A	24-10-1995
			DE	19503634 A	19-10-1995
			US	5707588 A	13-01-1998
DE 2709698	A	07-09-1978	NONE		
WO 9701085	A	09-01-1997	AU	6246396 A	22-01-1997
			CA	2224278 A	09-01-1997
			EP	0835435 A	15-04-1998